Know Cancer

or
forgot password

A Prospective Controlled Phase II Study of Preoperative Exisulind Therapy Initiated Prior to Radical Prostatectomy: Effect on Apoptosis


Phase 2
40 Years
N/A
Not Enrolling
Male
Prostatic Neoplasms

Thank you

Trial Information

A Prospective Controlled Phase II Study of Preoperative Exisulind Therapy Initiated Prior to Radical Prostatectomy: Effect on Apoptosis

Inclusion Criteria


Males 40 years of age and older with prostate cancer who are scheduled to undergo surgical
removal of the prostate at Mayo Clinic Rochester, Mayo Clinic Jacksonville, or Mayo Clinic
Arizona may be eligible for this protocol.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

4 week changes in apoptosis biomarkers

Principal Investigator

Bradley C. Leibovich, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic

Authority:

United States: Food and Drug Administration

Study ID:

2297-01

NCT ID:

NCT00166478

Start Date:

April 2002

Completion Date:

October 2007

Related Keywords:

  • Prostatic Neoplasms
  • Neoplasms
  • Prostatic Neoplasms

Name

Location
Mayo Clinic Rochester, Minnesota  55905